- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:02 | Revelation Biosciences, Inc.: REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | 90 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| Do | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| Do | Revelation Biosciences, Inc.: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | 259 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 27.02. | Revelation Biosciences reports FY results | 2 | Seeking Alpha | ||
| 26.02. | Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 | 308 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 29.01. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.01. | Revelation Biosciences kündigt Reverse-Split im Verhältnis 1:4 an | 3 | Investing.com Deutsch | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 26.01. | Revelation Biosciences to implement 1-for-4 reverse stock split | 3 | Investing.com | ||
| 26.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 | 689 | ACCESS Newswire | SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement... ► Artikel lesen | |
| 23.01. | Revelation Biosciences sichert sich Kapital durch Ausübungsvereinbarung für Optionsscheine | 3 | Investing.com Deutsch | ||
| 23.01. | Revelation Biosciences announces warrant exercise agreement | 1 | Investing.com | ||
| 23.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds | 386 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 23.01. | Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? | 11 | Benzinga.com | ||
| 22.01. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.01. | Revelation Biosciences, Inc.: Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI | 349 | ACCESS Newswire | - Single Phase 2/3 Adaptive Study Design -- Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company"... ► Artikel lesen | |
| 14.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology | 340 | ACCESS Newswire | - Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ACCESS Newswire / January 14, 2026 / Revelation Biosciences Inc. (NASDAQ:REVB) (the... ► Artikel lesen | |
| 12.01. | Revelation Biosciences, Inc.: Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 330 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing... ► Artikel lesen | |
| 07.01. | Revelation Biosciences begins GMP manufacturing for GEMINI trials | 1 | Investing.com | ||
| 07.01. | Revelation Biosciences startet GMP-Produktion für klinische Studien zu GEMINI | 4 | Investing.com Deutsch | ||
| 07.01. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development | 203 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 34,435 | +0,55 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| BIONTECH | 75,50 | -2,08 % | Nach eigenem Bekunden konzentriert sich BioNTech bei der Suche nach einem neuen CEO vor allem auf die USA | Der kürzlich angekündigte Rücktritt der BioNTech Gründer Ugur Sahin und Özlem Türeci sorgte für einen Schock an der Börse und auch anderswo für Unsicherheit. Die Stadt Mainz scheint bereits darum zu... ► Artikel lesen | |
| VALNEVA | 2,828 | -37,43 % | Valneva-Aktie crasht brutal - die Hintergründe | Lange Gesichter bei den Aktionären von Valneva. Das Papier der europäischen Impfstoff-Hoffnung crasht zur Stunde um rund 40 Prozent. Für eine Enttäuschung sorgen die lang erwarteten Phase-3-Studiendaten... ► Artikel lesen | |
| ARCELLX | 114,49 | -0,10 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| BB BIOTECH | 46,800 | -5,55 % | EQS-News: BB BIOTECH AG: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.25 pro Aktie | EQS-News: BB BIOTECH AG
/ Schlagwort(e): Hauptversammlung/Dividende
Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.25... ► Artikel lesen | |
| EVOTEC | 4,079 | -1,71 % | BYD im Freudentaumel, Rheinmetall bleibt beliebt bei Analysten, TUI bemüht sich um bessere Stimmung und Evotec verschnauft | Obschon der Krieg im Nahen Osten weitergeht und jegliche Anzeichen eines baldigen Endes vermissen lässt, wagten die Börsen sich am Montag an eine minimale Erholung. Es darf allerdings bezweifelt werden... ► Artikel lesen | |
| IMMUNITYBIO | 6,190 | -16,55 % | ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy | ||
| OCUGEN | 1,585 | -8,78 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 72,63 | -8,25 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TANGO THERAPEUTICS | 19,360 | +2,11 % | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| ERASCA | 14,660 | +2,45 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| VERA THERAPEUTICS | 39,230 | -3,73 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,240 | -2,43 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| MODERNA | 45,225 | +2,00 % | Pfizer vs Moderna: Which Pharma Stock Has More Upside? | ||
| COGENT BIOSCIENCES | 35,010 | -1,10 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen |
Das Unternehmen REVELATION BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,190 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.